Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Dabigatran, a direct thrombin inhibitor, has robust data for the treatment of deep venous
thrombosis and pulmonary embolism, stroke prevention in non-valvular atrial fibrillation, and …

Background: Direct oral anticoagulants have been developed to address some of the
drawbacks of vitamin-K antagonists. However, special attention should be given when using …

Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …

Introdução e objetivos Os novos anticoagulantes orais são opções emergentes para a
prevenção e tratamento das doenças tromboembólicas. São cada vez mais usados na …

Methods: We describe baseline data and treatment patterns of patients recruited in Belgium
in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Background: Novel oral anticoagulants (NOACs) have shown to be both safe and effective
for ischemic stroke prevention in patients with nonvalvular atrial fibrillation (NVAF). We …

Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …

For more than 5 decades, the only available treatment for the prevention of atrial fibrillation
(AF)-related stroke were the vitamin K antagonists. Recently, novel oral anticoagulants …